tirzepatide glp1 gip Bumps and humps in the success of as the first and receptor agonist GLP-1 & GIP Weight Loss

Van Elslande, J

Health Canada authorized ZEPBOUND KwikPen as a once-weekly injection for chronic weight management, as an adjunct to diet and exercise, for adults living with obesity (with a BMI of 30 kg/m2 or greater), or overweight (with a BMI of 27 kg/m2 to less than 30 kg/m2) and also have at least one weight-related medical condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease

Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)

Retrieved from Bouchaud, C

Important Notes Practical points that keep weekly administration safe and consistent

However, many people find that their body adapts more quickly to each subsequent dose increase because the underlying mechanisms (caloric deficit, metabolic adaptation) are already partially adjusted